Analysts love these EV-related stocks, giving 2 of them more than 100% upside
CNBC Pro screened the Global X Autonomous and Electric Vehicles ETF for stocks with more than 30% upside over the next 12 months — and one was given 208%.
Barry Silbert’s crypto empire continues to spiral as ex-NYSE president buys news site CoinDesk
The sale of digital currency news site CoinDesk is the latest sign that Barry Silbert’s crypto empire is dwindling
Stocks slide as November rally pauses on some weak retail earnings: Live updates
Stocks were down Tuesday as traders assessed some disappointing retail results and looked ahead to the release of the Federal Reserve meeting minutes.
Asia markets largely rise as Hong Kong, Taiwan lead gains on tech bounce
Investors will assess South Korean producer prices for October, as well as New Zealand’s October trade figures.
CNBC Daily Open: Record highs for Microsoft and Nvidia
All the turmoil at OpenAI over the weekend turned out pretty well — for Sam Altman and Microsoft, at least.
Sam Altman says successful people ‘believe in themselves almost to the point of delusion’—that’s frightening, says expert
Ex-OpenAI CEO Sam Altman wrote in 2019 that “almost too much self-belief” was a key to success. That presents problems, says a UC Berkeley leadership expert.
Microsoft CEO Nadella says OpenAI governance needs to change no matter where Altman ends up
Microsoft CEO Satya Nadella told CNBC on Monday that the company remains committed to OpenAI and Sam Altman after three days of drama
Crypto company led by former NYSE president acquires news outlet CoinDesk: CNBC Crypto World
CNBC Crypto World features the latest news and daily trading updates from the digital currency markets and provides viewers with a look at what’s ahead with high-profile interviews, explainers, and unique stories from the ever-changing crypto industry….
Successful people have more ‘productive paranoia’ than most, says bestselling author Jim Collins—here’s how to cultivate it
If you want success, you have to be paranoid about future events that could derail you, says bestselling author Jim Collins. He calls it “productive paranoia.”
This under-the-radar biopharma stock could more than double, Goldman Sachs says
This biotech stock could see 138% upside as its lead asset reaches regulatory approval, Goldman Sachs said.
